Skip to content Skip to footer
Subscribe Now
NEWS

Earendil Labs Inks $1.5B+ Research Collaboration with Genentech to Advance Bispecific Antibodies in Oncology

Shots: Earendil Labs has entered into a research collaboration with Genentech to discover and develop multiple therapeutic bispecific antibody programs in oncology Earendil Labs will lead antibody discovery & research through early clinical development for programs targeting certain pre-agreed target combinations, while Genentech will take over global clinical development & commercialization As per the deal,…
2 days ago

Read more

NEWS

QurCan Therapeutics Partners with Eli Lilly to Develop Nucleic Acid Therapies for CNS and PNS Diseases

Shots: QurCan Therapeutics has entered into an exclusive research & collaboration agreement with Eli Lilly for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS) Lilly & QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicines for CNS & PNS delivery, with QurCan…
September 15, 2026

Read more

EVENTS

Digi-Tech Pharma & AI 2027 | May 11-12 | London, UK

The pharmaceutical and healthcare industries are entering a new era of technology-led transformation, with artificial intelligence, machine learning, data science, informatics, and advanced data management reshaping how medicines are discovered, developed, and delivered. Against this backdrop, Digi-Tech Pharma & AI 2027 will bring together senior professionals, technology leaders, decision-makers, and innovators from the pharmaceutical, biotechnology,…
August 19, 2026

Read more

NEWS

OmniAb and Eli Lilly Partner on New Ion Channel Discovery Program

Shots: OmniAb has entered a global collaboration & license agreement with Eli Lilly for a new ion channel program, leveraging OmniAb’s discovery & screening platform to identify next-generation therapeutics targeting ion channels The therapeutic target and modality remain undisclosed, while OmniAb will contribute its established expertise and technology in ion channel discovery & screening As…
August 17, 2026

Read more

MAGAZINE

PharmaShots Magazine-Aug-2026 Edition

Shots:  This edition explores Tailored Therapy, Smarter Decisions: AI in Personalized Medicine, highlighting how artificial intelligence, machine learning, multi-omics, real-world data, and predictive analytics are transforming personalized medicine into a more precise, data-driven, and patient-centric approach to care, enabling better patient stratification, treatment selection, and clinical decision-making. Through expert perspectives, feature stories, and industry insights,…
August 13, 2026

Read more

NEWS

Almirall Partners with CrystalO to Advance Novel Small Molecules in Medical Dermatology

Shots: Almirall & CrystalO have partnered to advance drug discovery research in medical dermatology, leveraging CrystalO's scientific expertise in ion channels with Almirall's experience in medical dermatology R&D As per the deal, CrystalO will use its AI & structure-based drug discovery platform for compound discovery, optimization, IND-enabling studies, & early clinical development through PoC. Almirall…
August 10, 2026

Read more

NEWS

Ono and Mediar Partner to Develop Antibody Therapies for Fibro-Inflammatory Diseases

Shots: Ono has entered into a drug discovery partnership & option agreement with Mediar Therapeutics to develop novel antibody therapeutics for fibro-inflammatory diseases As per the deal, Mediar will conduct research using its fibrosis-focused research platform, while Ono will gain exclusive worldwide option rights to select candidates for development, manufacturing, & commercialization The partnership will…
August 7, 2026

Read more

Load more